AI
PRTK

Axiom Investors’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Axiom Investors’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-49,752
Closed -$1.25M – 159
2017
Q3 		$1.25M Sell
49,752
-14,130
-22% -$329K 0.03% 128
2017
Q2 		$1.54M Buy
+63,882
New +$1.41M 0.04% 130

Other funds holding PRTK

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Axiom Investors's PRTK Position: Q4 2017 in Review

Axiom Investors sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q4 2017, closing a stake of 49,752 shares — an estimated $1.25M sold.

Axiom Investors first reported a position in PRTK in Q2 2017 and held it in 2 quarters. The position peaked at $1.54M in Q2 2017. 116 funds tracked by Wall St. Rank hold PRTK as of Q4 2017.

  • Axiom Investors reported no remaining Paratek Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
  • Axiom Investors sold 49,752 Paratek Pharmaceuticals, Inc. shares in Q4 2017, an estimated $1.25M.
  • Axiom Investors first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2017 and held it in 2 quarters.
  • Axiom Investors's Paratek Pharmaceuticals, Inc. position peaked at $1.54M in Q2 2017.
  • 116 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q4 2017.

Based on Axiom Investors's 13F filing for Q4 2017, filed 14 Feb 2018.